Adamis Pharmaceuticl (ADMP) 6.21 $ADMP
Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles
M2 - Mon Apr 28, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zbrdd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Vical Incorporated - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Nutra Pharma Corporation - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - Spider Biotech S.r.l. - Kala Pharmaceuticals, Inc. - Coridon Pty Ltd - Sanofi Pasteur SA - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - amenamevir - tenofovir - RPI-78M - RPI-MN - HSV-2 Vaccine - CEL-1000 - HSV Vaccine - HSV-2 Vaccine - C-31-G - MucoCept Platform - HSV-2 Px - NVC-727 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - GV-2207 - MB-66 - Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - BA-368 - HSV-2 Vaccine - RKP-00156 - CEL-1000 - MAb hu2c - HSV Vaccine - Drug For Herpes Simplex Virus - Subunit Vaccine for Herpes Simplex Virus 2 - Small Molecules for Viral Infections - Small Molecules for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/2z...es_simplex
Global Perennial Allergic Rhinitis Pipeline Review 2014 - Analysis of 10 Company Profiles & 12 Drug Profiles
M2 - Thu Apr 17, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8vtlcw/perennial) has announced the addition of the "Perennial Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Perennial Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Perennial Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Merck & Co., Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - GenMont Biotech Inc. - VentiRx Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - Trimel BioPharma SRL - Hanmi Pharmaceuticals, Co. Ltd. Drug Profiles - desloratadine - fluticasone furoate - Qnasl - S-555739 - beclomethasone dipropionate - GMNL-32 - (montelukast sodium levocetirizine) - APC-3000 - VTX-1463 - TBS-6 - PF-06444753 - PF-06444752 For more information visit http://www.researchandmarkets.com/research/8vtlcw/perennial
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Mar 28, 5:00AM CDT
Keep these under-$10 biotech stocks on your radar.
4 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 14, 5:30AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Adamis Pharmaceuticals Corporation awarded notice of allowance for US patent that covers its cancer immunology portfolio
M2 - Mon Jan 27, 6:23AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) said on Friday that it has received a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the US.
Adamis Receives Notice of Key Allowance for US Patent That Supports Its Cancer Immunology Portfolio
Marketwire - Fri Jan 24, 7:00AM CST
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States. Notice of Allowance is the final step in the issuance of a patent. The company believes that this patent will significantly strengthen Adamis' cancer immunotherapy patent portfolio and will further support its TeloB-VAX vaccine technology. Claims to a patent entitled "Composition and Method for Inducing and Enhancing a Telomerase Reverse Transcriptase-Reactive Cytotoxic T Lymphocyte Response" have been allowed. These include claims for peptides that induce or enhance a cytotoxic T cell immune response against the human tumor antigen telomerase reverse transcriptase.
Adamis Pharmaceuticals Announces Full Exercise of Underwriter's Over-Allotment Option
Marketwire - Mon Jan 13, 6:01AM CST
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 558,000 shares of common stock at a public offering price of $5.95 per share in connection with its previously announced underwritten public offering of 3,720,000 shares of common stock, bringing the expected total gross proceeds from the offering to approximately $25,454,100, before underwriting discounts and commissions and other offering expenses and before any use of the proceeds by the company. The sale of the additional shares is expected to close on January 16, 2014, subject to customary closing conditions.
Adamis Pharmaceuticals Corporation acquires assets from 3M Company and 3M Innovative Properties Company for final payment of USD7m
M2 - Wed Jan 08, 5:50AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) announced on Tuesday the final payment of USD7m to fully acquire certain intellectual property and assets relating to Taper Dry Powder Inhaler technology under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Adamis Pharmaceuticals Announces Completion of Acquisition
Marketwire - Tue Jan 07, 8:30AM CST
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that at a closing held on December 27, 2013, it made a final payment of $7 million to fully acquire from 3M Company and 3M Innovative Properties Company certain intellectual property and assets relating to 3M's Taper Dry Powder Inhaler technology under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Adamis intends to utilize the assets initially to undertake efforts to develop a dry powder inhaler device for the treatment of asthma and COPD to deliver the same active ingredients as GlaxoSmithKline's Advair Diskus(R). The intellectual property includes patents, patent applications and other intellectual property relating to the Taper assets.
Adamis Pharmaceuticals Corporation concludes public offering of 3.72m common shares
M2 - Thu Dec 19, 5:45AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) stated on Wednesday that it has completed the public offering of 3,720,000 shares of its common stock
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
Marketwire - Wed Dec 18, 10:54AM CST
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share. The gross proceeds to Adamis from the offering are $22,134,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Adamis.
Epinephrine Auto-Injector Market - 2013 Report
M2 - Wed Dec 18, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/9db2mb/global) has announced the addition of the "Epinephrine Auto-Injector Market - 2013 Report" report to their offering. Global Epinephrine Auto-Injector Market Is Expected To Grow At A CAGR Of 13.34 Percent Over The Period 2012-2016 According to the report, though epinephrine is produced in the body, chemically synthesized epinephrine drugs are used in the treatment of anaphylactic shock that occurs in people who are suffering from allergy, cardiac arrest, and asthma. The increase in the number of people who are allergic to food, food additives, dust, and insect venom has led to an increase in the use of epinephrine drugs. This is one of the major factors that drive the growth of the Global Epinephrine Auto-injector market. Vendors are increasing their investment in R&D to develop a CFC-free epinephrine inhaler using hydrofluoroalkane as a propellant. Further, the report states that one of the main challenges in the market is that epinephrine drugs can cause adverse side effects such as vomiting, cardiac arrhythmia, hyperuricemia, lactic acidosis, pulmonary edema, and cerebral hemorrhage. Hence, physicians prefer to prescribe immunotherapy and other alternative pharmacotherapy drugs for the treatment of allergies. Key Topics Covered 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Rate of Incidence and Prevalence 10. Vendor Landscape 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Key Vendor Analysis Companies Mentioned - Adamis Pharmaceuticals - ALK Abello - Amedra Pharmaceuticals - Antares Pharma - Hospira - Intelliject - Lincoln Medical - Mylan - Sanofi - Teva Pharmaceuticals Industries For more information visit http://www.researchandmarkets.com/research/9db2mb/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Adamis Pharmaceuticals Corporation prices public offering of common shares, completes reverse common stock split & begins trading on The NASDAQ Capital Market
M2 - Mon Dec 16, 6:20AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) stated on Friday that it has priced an underwritten public offering of 3,720,000 shares of common stock.
Adamis Pharmaceuticals Announces Pricing of Public Offering of 3,720,000 Shares of Common Stock, Listing on NASDAQ, Reverse Stock Split
Marketwire - Fri Dec 13, 8:00AM CST
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are expected to be approximately $22,134,000, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are being sold by Adamis. The offering is expected to close on December 18, 2013, subject to customary closing conditions. In connection with the offering, Adamis has completed a 1-for-17 reverse stock split of its common stock which is effective as of December 13, 2013. The common stock began trading, on a split-adjusted basis, on The NASDAQ Capital Market under the symbol "ADMP" on December 13, 2013. In connection with its listing on The NASDAQ Capital Market, the company's common stock will cease trading on the OTC QB.
Adamis Pharmaceuticals Corporation plans public offering of common shares and warrants
M2 - Thu Nov 21, 4:10AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (OTCQB:ADMP) said on Wednesday that it has filed up to USD25m in registration statement on Form S-1 with the Securities and Exchange Commission for a proposed public offering of common stock and warrants.
Adamis Pharmaceuticals Announces Proposed Public Offering
Marketwire - Wed Nov 20, 8:30AM CST
Adamis Pharmaceuticals Corporation (OTCQB: ADMP) today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of common stock and warrants. The filing covers up to $25 million in securities. In connection with the anticipated closing of the proposed offering, Adamis expects to effect a reverse stock split of its common stock and list on the Nasdaq Capital Market.
Adamis Announces Positive Results of Study Concerning C31G in Treating Herpes Simplex Virus (HSV) Eye Infection
Marketwire - Mon Sep 09, 8:30AM CDT
Adamis Pharmaceuticals Corporation (OTCQB: ADMP) today announced that a recently published study conducted by university researchers found that the company's antimicrobial and spermicidal agent, C31G, was effective in treating Herpes Simplex Virus (HSV) in an eye infection (ocular keratitis) animal model. Adamis previously reported that C31G successfully completed a Phase 3 contraceptive clinical trial in humans conducted by the National Institute of Child Health and Human Development.
Contraception - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Contraception
M2 - Tue Sep 03, 4:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xvz9l7/contraception) has announced the addition of the "Contraception - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Contraception - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Contraception, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Contraception. Scope - A snapshot of the global therapeutic scenario for Contraception. - A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Contraception pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 ANI Pharmaceuticals, Inc. Adamis Pharmaceuticals Corporation Agile Therapeutics, Inc. Antares Pharma, Inc. Bayer AG CG Therapeutics, Inc. CONRAD HRA Pharma, SA Hydra Biosciences, Inc. Intas Pharmaceuticals Ltd. Ligand Pharmaceuticals Incorporated Merck & Co., Inc. Pantarhei Bioscience BV Teva Pharmaceutical Industries Limited TheraKine Inc. Watson Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/xv...traception About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Adamis Pharmaceuticals Corporation wins patent allowance in the US for prostate cancer drug, APC-100
M2 - Thu Aug 22, 7:12AM CDT
Biopharmaceutical company Adamis Pharmaceuticals Corporation (OTCQB:ADMP) reported on Wednesday the receipt of the US Notice of Allowance for its patent application for the development of APC-100 for the treatment of prostate cancer.
Adamis Prostate Cancer Drug Receives Allowance for Patent in USA
Marketwire - Wed Aug 21, 8:30AM CDT
Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, today announced the technology which constitutes its compound APC-100 received a Notice of Allowance for its patent application in the USA. Broad claims to a patent titled "Chroman-Derived Anti-Androgens for Treatment of Androgen-Mediated Disorders" have been allowed. These include claims for the use of APC-100 to reduce effects of androgens on androgen receptor expressing cancer cells, such as prostate cancer cells. Notice of Allowance is the final step in the issuance of a patent. This patent will significantly strengthen Adamis' patent portfolio for the use of APC-100 in the treatment of prostate cancer. Adamis currently has two other small molecule drugs that are being developed for the treatment of prostate cancer.
Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles
M2 - Mon Apr 28, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zbrdd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Vical Incorporated - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Nutra Pharma Corporation - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - Spider Biotech S.r.l. - Kala Pharmaceuticals, Inc. - Coridon Pty Ltd - Sanofi Pasteur SA - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - amenamevir - tenofovir - RPI-78M - RPI-MN - HSV-2 Vaccine - CEL-1000 - HSV Vaccine - HSV-2 Vaccine - C-31-G - MucoCept Platform - HSV-2 Px - NVC-727 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - GV-2207 - MB-66 - Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - BA-368 - HSV-2 Vaccine - RKP-00156 - CEL-1000 - MAb hu2c - HSV Vaccine - Drug For Herpes Simplex Virus - Subunit Vaccine for Herpes Simplex Virus 2 - Small Molecules for Viral Infections - Small Molecules for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/2z...es_simplex
Global Perennial Allergic Rhinitis Pipeline Review 2014 - Analysis of 10 Company Profiles & 12 Drug Profiles
M2 - Thu Apr 17, 6:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8vtlcw/perennial) has announced the addition of the "Perennial Allergic Rhinitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Perennial Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Perennial Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Perennial Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Perennial Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Perennial Allergic Rhinitis - Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Merck & Co., Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - GenMont Biotech Inc. - VentiRx Pharmaceuticals, Inc. - Adamis Pharmaceuticals Corporation - Trimel BioPharma SRL - Hanmi Pharmaceuticals, Co. Ltd. Drug Profiles - desloratadine - fluticasone furoate - Qnasl - S-555739 - beclomethasone dipropionate - GMNL-32 - (montelukast sodium levocetirizine) - APC-3000 - VTX-1463 - TBS-6 - PF-06444753 - PF-06444752 For more information visit http://www.researchandmarkets.com/research/8vtlcw/perennial
3 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Fri Mar 28, 5:00AM CDT
Keep these under-$10 biotech stocks on your radar.
4 Stocks Under $10 Making Big Moves
at The Street - Fri Feb 14, 5:30AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Adamis Pharmaceuticals Corporation awarded notice of allowance for US patent that covers its cancer immunology portfolio
M2 - Mon Jan 27, 6:23AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) said on Friday that it has received a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the US.
Adamis Receives Notice of Key Allowance for US Patent That Supports Its Cancer Immunology Portfolio
Marketwire - Fri Jan 24, 7:00AM CST
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States. Notice of Allowance is the final step in the issuance of a patent. The company believes that this patent will significantly strengthen Adamis' cancer immunotherapy patent portfolio and will further support its TeloB-VAX vaccine technology. Claims to a patent entitled "Composition and Method for Inducing and Enhancing a Telomerase Reverse Transcriptase-Reactive Cytotoxic T Lymphocyte Response" have been allowed. These include claims for peptides that induce or enhance a cytotoxic T cell immune response against the human tumor antigen telomerase reverse transcriptase.
Adamis Pharmaceuticals Announces Full Exercise of Underwriter's Over-Allotment Option
Marketwire - Mon Jan 13, 6:01AM CST
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 558,000 shares of common stock at a public offering price of $5.95 per share in connection with its previously announced underwritten public offering of 3,720,000 shares of common stock, bringing the expected total gross proceeds from the offering to approximately $25,454,100, before underwriting discounts and commissions and other offering expenses and before any use of the proceeds by the company. The sale of the additional shares is expected to close on January 16, 2014, subject to customary closing conditions.
Adamis Pharmaceuticals Corporation acquires assets from 3M Company and 3M Innovative Properties Company for final payment of USD7m
M2 - Wed Jan 08, 5:50AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) announced on Tuesday the final payment of USD7m to fully acquire certain intellectual property and assets relating to Taper Dry Powder Inhaler technology under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Adamis Pharmaceuticals Announces Completion of Acquisition
Marketwire - Tue Jan 07, 8:30AM CST
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that at a closing held on December 27, 2013, it made a final payment of $7 million to fully acquire from 3M Company and 3M Innovative Properties Company certain intellectual property and assets relating to 3M's Taper Dry Powder Inhaler technology under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Adamis intends to utilize the assets initially to undertake efforts to develop a dry powder inhaler device for the treatment of asthma and COPD to deliver the same active ingredients as GlaxoSmithKline's Advair Diskus(R). The intellectual property includes patents, patent applications and other intellectual property relating to the Taper assets.
Adamis Pharmaceuticals Corporation concludes public offering of 3.72m common shares
M2 - Thu Dec 19, 5:45AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) stated on Wednesday that it has completed the public offering of 3,720,000 shares of its common stock
Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
Marketwire - Wed Dec 18, 10:54AM CST
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share. The gross proceeds to Adamis from the offering are $22,134,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Adamis.
Epinephrine Auto-Injector Market - 2013 Report
M2 - Wed Dec 18, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/9db2mb/global) has announced the addition of the "Epinephrine Auto-Injector Market - 2013 Report" report to their offering. Global Epinephrine Auto-Injector Market Is Expected To Grow At A CAGR Of 13.34 Percent Over The Period 2012-2016 According to the report, though epinephrine is produced in the body, chemically synthesized epinephrine drugs are used in the treatment of anaphylactic shock that occurs in people who are suffering from allergy, cardiac arrest, and asthma. The increase in the number of people who are allergic to food, food additives, dust, and insect venom has led to an increase in the use of epinephrine drugs. This is one of the major factors that drive the growth of the Global Epinephrine Auto-injector market. Vendors are increasing their investment in R&D to develop a CFC-free epinephrine inhaler using hydrofluoroalkane as a propellant. Further, the report states that one of the main challenges in the market is that epinephrine drugs can cause adverse side effects such as vomiting, cardiac arrhythmia, hyperuricemia, lactic acidosis, pulmonary edema, and cerebral hemorrhage. Hence, physicians prefer to prescribe immunotherapy and other alternative pharmacotherapy drugs for the treatment of allergies. Key Topics Covered 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Rate of Incidence and Prevalence 10. Vendor Landscape 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Key Vendor Analysis Companies Mentioned - Adamis Pharmaceuticals - ALK Abello - Amedra Pharmaceuticals - Antares Pharma - Hospira - Intelliject - Lincoln Medical - Mylan - Sanofi - Teva Pharmaceuticals Industries For more information visit http://www.researchandmarkets.com/research/9db2mb/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Adamis Pharmaceuticals Corporation prices public offering of common shares, completes reverse common stock split & begins trading on The NASDAQ Capital Market
M2 - Mon Dec 16, 6:20AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) stated on Friday that it has priced an underwritten public offering of 3,720,000 shares of common stock.
Adamis Pharmaceuticals Announces Pricing of Public Offering of 3,720,000 Shares of Common Stock, Listing on NASDAQ, Reverse Stock Split
Marketwire - Fri Dec 13, 8:00AM CST
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are expected to be approximately $22,134,000, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are being sold by Adamis. The offering is expected to close on December 18, 2013, subject to customary closing conditions. In connection with the offering, Adamis has completed a 1-for-17 reverse stock split of its common stock which is effective as of December 13, 2013. The common stock began trading, on a split-adjusted basis, on The NASDAQ Capital Market under the symbol "ADMP" on December 13, 2013. In connection with its listing on The NASDAQ Capital Market, the company's common stock will cease trading on the OTC QB.
Adamis Pharmaceuticals Corporation plans public offering of common shares and warrants
M2 - Thu Nov 21, 4:10AM CST
Biopharmaceutical company Adamis Pharmaceuticals Corporation (OTCQB:ADMP) said on Wednesday that it has filed up to USD25m in registration statement on Form S-1 with the Securities and Exchange Commission for a proposed public offering of common stock and warrants.
Adamis Pharmaceuticals Announces Proposed Public Offering
Marketwire - Wed Nov 20, 8:30AM CST
Adamis Pharmaceuticals Corporation (OTCQB: ADMP) today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of common stock and warrants. The filing covers up to $25 million in securities. In connection with the anticipated closing of the proposed offering, Adamis expects to effect a reverse stock split of its common stock and list on the Nasdaq Capital Market.
Adamis Announces Positive Results of Study Concerning C31G in Treating Herpes Simplex Virus (HSV) Eye Infection
Marketwire - Mon Sep 09, 8:30AM CDT
Adamis Pharmaceuticals Corporation (OTCQB: ADMP) today announced that a recently published study conducted by university researchers found that the company's antimicrobial and spermicidal agent, C31G, was effective in treating Herpes Simplex Virus (HSV) in an eye infection (ocular keratitis) animal model. Adamis previously reported that C31G successfully completed a Phase 3 contraceptive clinical trial in humans conducted by the National Institute of Child Health and Human Development.
Contraception - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Contraception
M2 - Tue Sep 03, 4:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xvz9l7/contraception) has announced the addition of the "Contraception - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Contraception - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Contraception, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Contraception. Scope - A snapshot of the global therapeutic scenario for Contraception. - A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Contraception pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 ANI Pharmaceuticals, Inc. Adamis Pharmaceuticals Corporation Agile Therapeutics, Inc. Antares Pharma, Inc. Bayer AG CG Therapeutics, Inc. CONRAD HRA Pharma, SA Hydra Biosciences, Inc. Intas Pharmaceuticals Ltd. Ligand Pharmaceuticals Incorporated Merck & Co., Inc. Pantarhei Bioscience BV Teva Pharmaceutical Industries Limited TheraKine Inc. Watson Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/xv...traception About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Adamis Pharmaceuticals Corporation wins patent allowance in the US for prostate cancer drug, APC-100
M2 - Thu Aug 22, 7:12AM CDT
Biopharmaceutical company Adamis Pharmaceuticals Corporation (OTCQB:ADMP) reported on Wednesday the receipt of the US Notice of Allowance for its patent application for the development of APC-100 for the treatment of prostate cancer.
Adamis Prostate Cancer Drug Receives Allowance for Patent in USA
Marketwire - Wed Aug 21, 8:30AM CDT
Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, today announced the technology which constitutes its compound APC-100 received a Notice of Allowance for its patent application in the USA. Broad claims to a patent titled "Chroman-Derived Anti-Androgens for Treatment of Androgen-Mediated Disorders" have been allowed. These include claims for the use of APC-100 to reduce effects of androgens on androgen receptor expressing cancer cells, such as prostate cancer cells. Notice of Allowance is the final step in the issuance of a patent. This patent will significantly strengthen Adamis' patent portfolio for the use of APC-100 in the treatment of prostate cancer. Adamis currently has two other small molecule drugs that are being developed for the treatment of prostate cancer.
